-
Mashup Score: 0Tweetorial 3: Not Just Another Monoclonal Antibody: Best Practices for Providing T-cell Therapies — Current Activities - 6 month(s) ago
Differentiating Bispecifics & CAR-T for Relapsed Refractory Multiple Myeloma Tweetorial 3: Not Just Another Monoclonal Antibody: Best Practices for Providing T-cell Therapies This activity is jointly provided by Global Education Group and Bonum…
Source: Current ActivitiesCategories: Hem/Oncs, Latest HeadlinesTweet-
#mmsm ↪️ Need on the who, what, where, how to provide #BCMA-directed T-cell tx for #Myeloma? 📚 Lots to learn w @mvmateos & me 👇#MedTweetorial🧵 🏆 🆓#CME 👉🏼https://t.co/q4DprzNF7G Supported by educational grants from @JanssenUS & @Pfizer 🏁What’s your specialty?
-
-
Mashup Score: 1Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy - 8 month(s) ago
Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed clinical outcomes …
Source: www.ncbi.nlm.nih.govCategories: Hem/Oncs, Latest HeadlinesTweet-
#RWD on prior #BCMA Rx in pts receiving Ide-cel #CAR-T. The authors propose future steps on how we can manage pts pre-BCMA CAR-T! ? moving towards different antigen targeting +/- different modality of T-cell targeting ! Lots of ❓🙋 for us to answer :) https://t.co/Att1txSdCi https://t.co/cgKeTE9h0v
-
-
Mashup Score: 0Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial - 8 month(s) ago
Advances in Therapy – Patients with triple-class exposed relapsed/refractory multiple myeloma (RRMM) have poor outcomes with substantial healthcare costs. Idecabtagene vicleucel (ide-cel), a B-cell…
Source: link.springer.comCategories: Hem/Oncs, Latest HeadlinesTweet-
#CAR-T therapies are expensive upfront, but long term they reduce healthcare utilization! We saw this with CD19 CAR-T, exciting to see this replicated in #MMsM with #BCMA CAR-T https://t.co/qaIzCZJcjR https://t.co/xyVLrDLGed
-
-
Mashup Score: 4BCMA-targeted therapies for MM part I: ADCs and bsAb - 9 month(s) ago
Here, we summarize the latest on BCMA-targeted antibody-drug conjugates and bispecific antibody therapies, presenting the up-to-date clinical data available on these therapies.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The BCMA revolution! Read about the classes of BCMA-targeted therapeutics under investigation for the treatment of MM, starting here with part I on ADCs and bsAb. 👉 https://t.co/BkDtUJksI6 #myeloma #mmsm #BCMA #ASCO23 #EHA2023 https://t.co/KY1I7tCcGN
-
-
Mashup Score: 0Teclistamab Plus Talquetamab to Simultaneously Target BCMA and GPRC5D in Patients With R/R Multiple Myeloma - 9 month(s) ago
At the 2023 ASCO Annual Meeting, Yael C Cohen, MD, presents results of the RedirecTT-1 study of the combination of teclistamab and talquetamab for the treatment of patients with R/R multiple myeloma.
Source: www.hmpgloballearningnetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At the 2023 ASCO Annual Meeting #ASCO2023, Yael Cohen, MD, presented results of the RedirecTT-1 trial on the combination of #teclistamab and #talquetamab targeting bispecifics #BCMA and #GPRC5D for patients with #MultipleMyeloma. https://t.co/3uEGrm90CW @ASCO https://t.co/05oaUOiWI6
-
-
Mashup Score: 4
Cartesian Therapeutics and National Institute of Neurological Disorders and Stroke of the National Institutes of Health.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Congrats to Volkan Granit and entire study team. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study. #BCMA #tcellrx https://t.co/2reiazDC8h
-
-
Mashup Score: 1
Philip McCarthy, MD, from Roswell Park Cancer Institute provided an overview of CAR T-cell therapy, focusing on its application in multiple myeloma. CAR T-cell therapy involves genetically modifying T-cells to express a chimeric antigen receptor (CAR) that recognizes a specific antigen on tumor cells, such as BCMA (…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @PLMcCarthyMD: #BCMA #CARTcell https://t.co/gr37Z7UF6l
-
-
Mashup Score: 0Standard of Care the Safety and Efficacy of Cilta-cel for RRMM Patients - 11 month(s) ago
In this study, the researchers evaluated the use of standard of care (SOC) ciltacabtagene autoleucel in a patient population and compared it to the outcomes observed in the CARTITUDE-1 clinical trial. They found that a significant percentage of patients (57%) in the study population would have been ineligible for pa…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📢 ASCO 2023 🎉 🌟 #DorisHansenMD, from @MoffittNews, emphasized the need for further investigation into the impact of prior #BCMA exposure and outcomes. 🔬 The evaluation of #SOC #ciltacel in pts and compared to outcomes of the #CARTITUDE1 trial. 🔗 https://t.co/fSKJ02Rxp9 https://t.co/WE6W89dXMO
-
-
Mashup Score: 0ATRA, Crenigacestat Synergistically Augment BCMA on MM, BCMA-CAR T-Cell Efficacy | ASH Clinical News | American Society of Hematology - 12 month(s) ago
Skip Nav Destination April 4, 2023 Katie Robinson is a medical writer based in New York. In a pre-clinical study, all-trans retinoic acid (ATRA) treatment, alone or in combination with crenigacestat, led to enhanced B-cell…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Treatment with all-trans retinoic acid, alone or in combination with #crenigacestat, leads to enhanced #Bcell maturation antigen (#BCMA) expression on #multiplemyeloma (MM) cells, increasing the reactivity of BCMA-CAR #Tcells https://t.co/FJyXAAk2qA
-
-
Mashup Score: 0MajesTEC-1: Teclistamab in R/R MM Treatment - 1 year(s) ago
A look at BCMA targeting in relapsed/refractory multiple myeloma treatment and the BCMA-directed bispecific antibody teclistamab.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A look at #BCMA targeting in relapsed/refractory #multiplemyeloma treatment and the BCMA-directed bispecific antibody #teclistamab.@SagarLonialMD @WinshipAtEmory @MDAndersonNews @TulaneMedicine https://t.co/RnkKK5Jsbc
-
2/#MMsm @BonumCE @Global_CME ⚠️Important "need to know" items👇 1️⃣ - read CME ℹ️👉🏼https://t.co/q4DprzNF7G 2️⃣ - take the Pre-survey: https://t.co/1vp73c6uUt 3️⃣ - get all the info 👇 4️⃣ - claim your #CME 🏆 https://t.co/BITxNCTzHW